Format

Send to

Choose Destination
Heart Fail Clin. 2018 Jan;14(1):13-25. doi: 10.1016/j.hfc.2017.08.002.

Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides.

Author information

1
Division of Cardiovascular Medicine, VA San Diego Healthcare System 111-A, 3350 La Jolla Village Drive, San Diego, CA 92161, USA. Electronic address: amaisel@ucsd.edu.
2
Department of Internal Medicine, UC San Diego, 200 West Arbor Drive, La Jolla, San Diego, CA 92103, USA.
3
Division of Cardiovascular Medicine, UC San Diego, 9500 Gilman Drive MC 7411, La Jolla, San Diego, CA 92037-7411, USA.

Abstract

The natriuretic peptides play a vital role in normal physiology and as counter-regulatory hormones in heart failure (HF). Clinical assessment of their levels (for B-type natriuretic peptide [BNP], N-terminal proBNP, and the midregion of N-terminal pro-atrial natriuretic peptide) have become valuable tools in diagnosing patients with HF as well as risk stratifying and guiding therapy. Their roles have further expanded beyond HF to other cardiovascular conditions and for risk stratification in asymptomatic individuals. Understanding the clinical use of these hormones is vital to achieving their full potential.

KEYWORDS:

B-type natriuretic peptide; Diagnosis; Heart failure; Midregional pro‚Äďatrial natriuretic peptide; N-terminal B-type natriuretic peptide; Prognosis

PMID:
29153197
DOI:
10.1016/j.hfc.2017.08.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center